MME and prostate carcinoma: A high level of CD10 expression in primary tumor sample of prostate cancer is significantly associated with larger size of metastases, early death [50], and aggressive phenotype with a higher malignancy rate [33] and can be effectively used for stratifying prostate cancer outcome.